

THE UNIVERSITY OF TEXAS

MD Anderson
Cancer Center

Making Cancer History®

Development Office

T 713-792-3450
Unit 0705
P.O. Box 301439
Houston, Texas 77230-1439

January 24, 2020

Mrs. Taryn Hryc
Zeta Tau Alpha Houston Alumnae Association
7810 Braes Meadow Drive
Houston, Texas 77071

Dear Mrs. Hryc:

I recently joined MD Anderson as the senior vice president and chief development officer. I am incredibly proud to join this unique organization and to raise awareness and support for its mission to eliminate cancer. I know firsthand the pain and suffering cancer causes, as both of my parents and two of my grandparents succumbed to this terrible disease. Ending this scourge is a process, not an event: MD Anderson must pursue multiple clinical modalities and research paths over a period of time and have the financial and intellectual assets to pursue all promising opportunities for breakthroughs.

This long-term process to eradicate cancer is why your endowment is so critical. Endowments function as strategic ballast, providing steady and predictable income for our faculty in an otherwise unpredictable research funding environment. Your endowment thus yields sustainable funds for our exceptional faculty so that they have the freedom to launch innovative research projects, travel to seminars and conferences, purchase necessary equipment and supplies and train the next generation of talented cancer doctors and researchers.

On behalf of the 22,000 employees who are working toward the same goal, I thank you for your enduring gift of endowment support to keep this special institution moving forward today and tomorrow until the job gets done.

Sincerely,



Darrow Zeidenstein, Ph.D.
Senior Vice President and Chief Development Officer

DGZ:kh
Enclosures

If you do not want to receive certain fundraising communications from MD Anderson Cancer Center, please visit our website at www.mdanderson.org/FundraisingOptOut or contact us at 855-344-5272.

ENDOWMENT REPORT

Zeta Tau Alpha Houston Alumnae Association Fellowship

Naoto Ueno, M.D., Ph.D.
Breast Medical Oncology

FISCAL YEAR 2019	BEGINNING MARKET VALUE (SEPTEMBER 1, 2018) \$68,271.23	CASH DISTRIBUTIONS TO ENDOWMENT INCOME ACCOUNT \$3,064.36	ENDING MARKET VALUE (AUGUST 31, 2019) \$67,753.02
---------------------------------	--	--	---

HOW YOUR GIFT IS MAKING CANCER HISTORY[®]

We are very thankful for the Zeta Tau Alpha Houston Alumnae Association Fellowship through which the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic has funded inflammatory breast cancer (IBC) research. The endowed funds supported and recognized the exceptional efforts and contributions of two researchers who have the potential to make a substantial impact in improving IBC patient care across the world.

This research established the first immuno-competent mouse model to study the tumor microenvironment (TME) and immune response in IBC. It provides the premise for conducting multiple novel preclinical therapeutic studies. Our study also suggests that combination therapy with immune checkpoint inhibitors may potentiate the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in IBC. The therapeutic efficacy of PmAb and anti-PD-L1 combination in SUM149 humanized mice is in progress. The mechanism of how immune responses of triple-negative IBC

xenografts mediates the therapeutic efficacy of PmAb in IBC tumors remains to be investigated further.

The dual functions of TP-0903 targeted both IBC cells and macrophages possibly via the targeting of multiple kinases, including AXL and aurora B. The presenter examined the impact of TP-0903 on the cross-talk between IBC cells and macrophages in vitro and in vivo as well as the related mechanisms.

We are expanding collaboration by identifying the best ongoing research in the world. The selected awardees of this prestigious award will visit The University of Texas MD Anderson Cancer Center for their speaking engagement, providing opportunities for new collaborations.

The Zeta Tau Alpha award supported the selected researcher to travel and present at the 2018 San Antonio Breast Cancer Symposium. This presentation led to multiple manuscripts

(currently underway) and research presentation opportunities, including presentations at the annual American Association of Cancer Research meeting and selection for fifth annual Immunology Young Investigator Forum.

We are truly grateful for your unwavering support of our research, and the potential care our patients will receive from it. It is through commitment,

dedication and support from organizations like the Zeta Tau Alpha Houston Alumnae Association that we can continue our research efforts. Your funding has helped us provide effective, tailored treatments to improve outcomes for our patients suffering from IBC. Thank you again from all of us in the Morgan Welch IBC Research Program and Clinic.



THE UNIVERSITY OF TEXAS/TEXAS A&M
INVESTMENT MANAGEMENT COMPANY

ZETA TAU ALPHA HOUSTON ALUMNAE ASSOCIATION FELLOWSHIP

Year Established: 2010

Book Value: \$56,763.78

Activity from September 1, 2018 to August 31, 2019

Market value as of September 1, 2018 <i>The market value of investment holdings on the date specified.</i>	\$68,271.23
Net contributions and additions <i>New gifts and distributions/allocations reinvested to the endowment during this time period.</i>	--
Withdrawals <i>Funds withdrawn from the endowment. Withdrawals are generally made to address administrative adjustments or for term endowments.</i>	--
Net investment returns (losses) <i>Total net investment growth or loss to the value of the fund.</i>	2,925.45
Distributions and allocations:	
Distributions to endowment income account <i>These funds were made available for expenditure according to the purpose of the endowment.</i>	(3,064.36)
Support for fundraising efforts to increase philanthropy that benefits the mission of the institution <i>Institutions may elect to receive up to .60% (60 basis points) of average market value</i>	(379.30)
Total distributions and allocations	<u>(3,443.66)</u>
Market value as of August 31, 2019	<u><u>\$67,753.02</u></u>

Five-Year Investment History

YEAR ENDED 8/31	NET CONTRIBUTIONS (WITHDRAWALS)	INCOME REINVESTED	DISTRIBUTIONS/ ALLOCATIONS	INVESTMENT RETURN	TOTAL MARKET VALUE	TOTAL BOOK VALUE	LTF MARKET VALUE	LONG TERM FUND UNITS
2015	--	--	(2,994.40)	508.99	62,130.42	56,763.78	62,130.42	8,747.87
2016	--	--	(3,037.28)	2,154.83	61,247.97	56,763.78	61,247.97	8,747.87
2017	--	--	(3,067.88)	7,275.33	65,455.42	56,763.78	65,455.42	8,747.87
2018	--	--	(3,418.59)	6,234.40	68,271.23	56,763.78	68,271.23	8,747.87
2019	--	--	(3,443.66)	2,925.45	67,753.02	56,763.78	67,753.02	8,747.87

Endowment Account No.: 57800492

Endowment Distribution Percentage

Average Market Value for the Period Ended August 31, 2019
(Five-quarter average)

Total Distributions to
Endowment Income
Account as a % of
Average Market Value

\$66,945.90

4.58%

Endowment Performance

Endowment Return

One Year	3.89%
Three Years (Annualized)	8.31%
Five Years (Annualized)	5.83%
Ten Years (Annualized)	NA

Endowment return is net investment return less the .60% (60 basis points) to support fundraising efforts to increase philanthropy that benefits the mission of the institution.

Fees and Allocations Charged to Long Term Fund

Percent of Average
Market Value

Investment Management Fees (3 Year Average):

UTIMCO Management Services	0.09%
External Investment Manager Fees	1.99%
Other Investment Management Costs	0.03%

UT System Administration:

Endowment Management and Administration	0.019%
Investment Oversight Fee	0.001%

UT System Institutions:

Support for fundraising efforts to increase philanthropy that benefits the mission of the institution	Institutions may elect to receive up to 0.60%
---	---

Endowment Account No.: 57800492